Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer

Chemotherapy

Volumn 56, Issue 6, 2010, Pages 436-443

  Hasegawa, Hiroko ^a   Fujitani, Kazumasa ^a   Kurokawa, Yukinori ^a   Hirao, Motohiro ^a   Nakazuru, Shoichi ^a   Mita, Eiji ^a   Tsujinaka, Toshimasa ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Adjuvant chemotherapy; Efficacy of chemotherapy; Overall survival; Recurrent gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; FLOXURIDINE; IRINOTECAN; UFT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTRECTOMY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; RECURRENCE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TEGAFUR; TREATMENT OUTCOME;

EID: 78349279273     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317762     Document Type: Article

References (25)

1. Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, Van de Velde CJH: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447
2. Pignon J, Decreux M, Rougier P: Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 1994; 12: 877-878
3. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a metaanalysis of randomised trials. Eur J Cancer 1999; 35: 1059-1064
4. Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, Cascinu S, Barni S, Labianca R, Torri V: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. Ann Oncol 2000; 11: 837-843
5. Janunger K, Hafstrom L, Nygren P, Glimelius B: A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309-326 (Pubitemid 32588125)
6. Panzini I, Gianni L, Fattori P, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A: Adjuvant chemotherapy in gastric cancer: a metaanalysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002; 88: 21-27
7. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730
8. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
9. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, for the ACTS-GC Group: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820
10. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216 (Pubitemid 30099779)
12. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, Ohtsu A: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer. (JCOG 9912). J Clin Oncol 2007; 25:LBA4513
13. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drug 1996; 7: 548-557
14. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221
15. Uedo N, Narahara H, Ishihara R, Takiuchi H, Goto M, Fujitani K, Hirao M, Tsujinaka T, Imano M, Furukawa H, Tsukuma H, Taguchi T: Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 2007; 73: 65-71
16. Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H, Taguchi T: Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 2008; 74: 37-41
17. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Nakao A: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007; 27: 2667-2672
18. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T, Ogawa N: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1033-1038 (Pubitemid 24225031)
19. Koizumi W, Kurihara M, Satoh A, Takiuchi H, Tanabe S, Shimada K, Iwasaki R, Saigenji K: Phase I/II study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res 2005; 25: 1257-1262 (Pubitemid 40546799)
20. O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, André T, Haller DG, Sargent DJ: Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 2008; 26: 2336-2341
21. Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 764-773
22. Shitara K, Muro K, Ura T, Takahari D, Yokota T, Sawaki A, Kawai H, Ito S, Yamamura Y: Chemotherapy for gastric cancer that recurs after adjuvant chemotherapy with S-1. Jpn J Clin Oncol 2008; 38: 786-789
23. Eskiocak U, Eri OD, Kars MD, Biçer A, Gunduz U: Effect of doxorubicin on telomerase activity and apoptotic gene expression in doxorubicin-resistant and -sensitive MCF-7 cells. Chemotherapy 2008; 54: 209-216
24. Ishido K, Azuma M, Koizumi W, Takeuchi A, Sakuramoto S, Watanabe M, Okayasu I: Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy. Pharmacogenet Genomics 2009; 19: 955-964
25. Yasumatsu R, Nakashima T, Uryu H, Ayada T, Wakasaki T, Kogo R, Masuda M, Fukushima M, Komune S: Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma. Chemotherapy 2009; 55: 36-41